Kiniksa Pharmaceuticals International (KNSA) Common Equity (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Common Equity came in at $654.1 million in Q2 2026, up 32.15% YoY from $495.0 million in Q2 2025, and up 8.0% on a QoQ basis from $605.7 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Common Equity (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Common Equity data on file, last reported at $654.1 million in Q2 2026.
- Quarterly Common Equity rose 32.15% year-over-year to $654.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $654.1 million (up 32.15% YoY) and the FY2025 annual result came in at $567.6 million, up 29.46% from the prior year.
- Common Equity climbed to $654.1 million in Q2 2026, from $605.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $654.1 million in Q2 2026 to a low of $153.5 million in Q2 2022.
- A 5-year average of $433.5 million and a median of $436.1 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity tumbled 38.59% — and 2023, when it surged 168.19%.
- Tracing KNSA's Common Equity over 5 years: stood at $396.1 million in 2022, then grew by 10.78% to $438.8 million in 2023, then retreated by 0.09% to $438.4 million in 2024, then gained by 29.46% to $567.6 million in 2025, then climbed by 15.25% to $654.1 million in 2026.
- The last three Common Equity figures came in at $654.1 million (Q2 2026), $605.7 million (Q1 2026), and $567.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Kiniksa Pharmaceuticals International | 6.05 Bn | 5.52 Bn | 220.03 Mn | 654.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 654.15 Mn |
| Mar 31, 2026 | 605.69 Mn |
| Dec 31, 2025 | 567.61 Mn |
| Sep 30, 2025 | 535.38 Mn |
| Jun 30, 2025 | 495.01 Mn |
| Mar 31, 2025 | 457.49 Mn |
| Dec 31, 2024 | 438.44 Mn |
| Sep 30, 2024 | 437.01 Mn |
| Jun 30, 2024 | 435.10 Mn |
| Mar 31, 2024 | 431.90 Mn |
| Dec 31, 2023 | 438.84 Mn |
| Sep 30, 2023 | 405.13 Mn |
| Jun 30, 2023 | 411.66 Mn |
| Mar 31, 2023 | 390.10 Mn |
| Dec 31, 2022 | 396.15 Mn |
| Sep 30, 2022 | 384.01 Mn |
| Jun 30, 2022 | 153.49 Mn |
| Mar 31, 2022 | 166.24 Mn |
| Dec 31, 2021 | 185.04 Mn |
| Sep 30, 2021 | 214.05 Mn |